

# Trodelvy® (Sacituzumab Govitecan-hziy) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

## Drug Information

Physician billing (HCPCS code: \_\_\_\_\_)  Pharmacy billing (NDC: \_\_\_\_\_)

Dose: \_\_\_\_\_ Regimen: \_\_\_\_\_ Start Date (or date of next dose): \_\_\_\_\_

## Billing Provider Information

Provider NPI: \_\_\_\_\_ Provider Name: \_\_\_\_\_

Provider Phone: \_\_\_\_\_ Provider Fax: \_\_\_\_\_

## Prescriber Information

Prescriber NPI: \_\_\_\_\_ Prescriber Name: \_\_\_\_\_

Prescriber Phone: \_\_\_\_\_ Prescriber Fax: \_\_\_\_\_ Specialty: \_\_\_\_\_

## Criteria

### For Initial Authorization

#### 1. Please indicate the diagnosis and information:

**Breast Cancer**

A. Does the member have a diagnosis of triple-negative breast cancer? Yes  No

i. Does the member have unresectable locally advanced or metastatic disease?  
Yes  No

ii. Has the member received 2 or more prior therapies, at least 1 of which was for metastatic disease? Yes  No

B. Does the member have a diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer? Yes  No

i. Does the member have unresectable locally advanced or metastatic disease?  
Yes  No

ii. Has the member received endocrine-based therapy and  $\geq 2$  additional systemic therapies in the metastatic setting? Yes  No

**Urothelial Cancer**

A. Does the member have unresectable, locally advanced or metastatic disease? Yes  No

B. Has the member previously received a platinum-containing chemotherapy? Yes  No

C. Has the member previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor? Yes  No

If answer is none of the above, please indicate diagnosis: \_\_\_\_\_

Additional Information: \_\_\_\_\_

#### CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

# Trodelvy® (Sacituzumab Govitecan-hziy) Prior Authorization Form

Member Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_ Member ID#: \_\_\_\_\_

**For Continued Authorization:**

1. Date of last dose: \_\_\_\_\_
2. Does member have any evidence of progressive disease while on sacituzumab govitecan-hziy? Yes   
No
3. Has the member experienced adverse drug reactions related to sacituzumab govitecan-hziy therapy?  
Yes  No   
*If yes, please specify adverse reactions:* \_\_\_\_\_

Additional information: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Please complete and return all pages. Failure to complete all pages will result in processing delays.

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.**

*Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to **888-601-8461** or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at **AetnaBetterHealth.com/Oklahoma.**

CONFIDENTIALITY NOTICE

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*